

Letter

Co-incident increase in gene copy number of *ERBB2* and *LRIG1* in breast cancerIngrid Ljuslinder¹, Irina Golovleva², Roger Henriksson¹, Kjell Grankvist³, Beatrice Malmer¹ and Håkan Hedman¹¹Department of Radiation Sciences, Oncology, Umeå University Hospital, SE-90187, Umeå, Sweden²Department of Medical Biosciences, Medical and Clinical Genetics, SE-90187, Umeå, Sweden³Department of Medical Biosciences, Clinical Chemistry, Umeå University, SE-90187, Umeå, Sweden⁴Department of Pathology, Umeå University, SE-90187, Umeå, SwedenCorresponding author: Ingrid Ljuslinder, ingrid.ljuslinder@onkologi.umu.se

Published: 12 May 2009

This article is online at <http://breast-cancer-research.com/content/11/3/403>


© 2009 BioMed Central Ltd

Breast Cancer Research 2009, **11**:403 (doi:10.1186/bcr2248)See related research article by Ljuslinder *et al.*, <http://breast-cancer-research.com/content/7/5/R719>

Using fluorescence *in situ* hybridization (FISH), we previously showed that the *LRIG1* gene had an increased copy number in 11 of 28 (39%) breast cancer tumours [1]. The *LRIG1* gene (leucine-rich repeats and immunoglobulin-like domains 1) at chromosome 3p14 is a proposed tumour suppressor gene that negatively regulates various receptor tyrosine kinases, including the breast cancer proto-oncogene product *ERBB2* [2,3].

Recently, however, Miller and colleagues [4] showed that 10 of 13 (76%) *ERBB2*⁺ tumours had decreased *LRIG1* protein levels compared to normal breast tissue. As their data showed down-regulation at the protein level whereas our data showed an increased copy number at the genomic level, we analysed 45 additional breast tumours by FISH as previously described [1]. Thus, out of 73 tumours analysed to date, 25 (34%) did indeed have increased *LRIG1* copy number. To further analyse the relationship between *LRIG1* and *ERBB2* at the genomic level, we evaluated the *ERBB2* gene copy numbers in 18 tumours with increased *LRIG1* copy number using FISH analysis according to standard procedures. Interestingly, 16 (89%) out of the 18 tumours displayed increased copy number of *ERBB2* (Figure 1). This suggests that the majority of breast cancer tumours with increased copy number of *ERBB2* simultaneously had increased *LRIG1* copy number (our data) and decreased *LRIG1* protein levels [4].

We draw the following major conclusions from these results. First, as previously shown, a significant proportion of breast tumours have an increased *LRIG1* gene dosage. Second, there is a correlation between increased gene copy numbers

Figure 1

Increased copy number of *LRIG1* and *ERBB2* in human breast cancer in the same patient. Interphase nuclei from a breast cancer tumour were analysed by FISH. (a) A specific *LRIG1* probe (red) showed increased *LRIG1* copy number (five copies) whereas a specific centromere probe (CEP3) (green) showed normal chromosome 3 copy number (two copies). (b) A specific *ERBB2* probe (red) showed amplification of the *ERBB2* gene whereas a specific centromere probe (CEP17; green) showed three copies of chromosomes 17.

of *ERBB2* and *LRIG1*. Third, based on the Miller protein data, most of the tumours with increased *LRIG1* gene dosage express reduced levels of the *LRIG1* protein. This indicates a negative selection against *LRIG1* protein expression, supporting the notion that *LRIG1* is a tumour suppressor in breast cancer. Although the mechanism behind the down-regulation of *LRIG1* protein in breast cancer is not known, it has been reported that increased gene copy

FISH = fluorescence *in situ* hybridization.

numbers in some cases are associated with decreased mRNA expression [5]. In any case, the high frequency (34%) of tumours with increased *LRIG1* gene copy number implies a positive selection for tumour cells with this genomic alteration. It remains, however, to be elucidated whether the molecular driver behind the selective advantage associated with this alteration is *LRIG1* down-regulation *per se*. Other possibilities include activation of nearby proto-oncogenes or the generation of novel oncogenic fusion genes.

In summary, the co-incidental increase in copy number of *ERBB2* and *LRIG1* in breast cancer is a novel finding, pointing at a functional co-operation between these genetic events, where the biological and clinical importance need to be clarified further.

Competing interests

The authors declare that they have no competing interests.

References

1. Ljuslinder I, Malmer B, Golovleva I, Thomasson M, Grankvist K, Hockenstrom T, Emdin S, Jonsson Y, Hedman H, Henriksson R: **Increased copy number at 3p14 in breast cancer.** *Breast Cancer Res* 2005, **7**:R719-727.
2. Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, Amariglio N, Henriksson R, Rechavi G, Hedman H, Wides R, Yarden Y: **LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation.** *EMBO J* 2004, **23**:3270-3281.
3. Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway KL 3rd, Sweeney C: **The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.** *J Biol Chem* 2004, **279**:47050-47056.
4. Miller JK, Shattuck DL, Ingalla EQ, Yen L, Borowsky AD, Young LJ, Cardiff RD, Carraway KL 3rd, Sweeney C: **Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer.** *Cancer Res* 2008, **68**:8286-8294.
5. Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, Thorne N, Redon R, Bird CP, de Grassi A, Lee C, Tyler-Smith C, Carter N, Scherer SW, Tavaré S, Deloukas P, Hurles ME, Dermitzakis ET: **Relative impact of nucleotide and copy number variation on gene expression phenotypes.** *Science* 2007, **315**:848-853.